Gamma Vaccines
Melbourne, Australia· Est.
Australian biotech leveraging photon‑inactivated virus technology to create broad‑spectrum vaccines for flu, COVID‑19, and other viral threats.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Australian biotech leveraging photon‑inactivated virus technology to create broad‑spectrum vaccines for flu, COVID‑19, and other viral threats.
Infectious DiseasesAnimal Health
Technology Platform
Photon‑inactivation of purified or genetically modified viruses, preserving native epitopes to induce broad humoral and cellular immunity without adjuvants.
Opportunities
Successful preclinical data could unlock partnerships with large pharma for rapid pandemic vaccine deployment and broaden the platform to animal health markets.
Risk Factors
Technology validation risk, limited financial runway, and competition from established vaccine manufacturers could delay clinical progression.
Competitive Landscape
Differentiates from traditional chemically inactivated vaccines by preserving viral structure for stronger T‑cell responses, but competes with mRNA and viral‑vector platforms that have faster development timelines.